Together, these results indicate that inhibition of MAP4K4 in VSMCs lacking RhoA suppresses AAA formation, rescues the contractility of VSMCs, and attenuates vascular inflammation and ECM degradation through inactivation of the MAP kinase signaling. This evidence concerns the gene RHOA and triple-A syndrome.